| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in December |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 |
| 04 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting |
| 02 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program |
| 24 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer |
| 13 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 |
| 16 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders (the “Annual Meeting”) of Cullinan Therapeutics, Inc. (the “Company”) was held on June 16, 2026. The holders present voted on the three proposals presented at the Annual Meeting as follows. |
| 10 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases |
| 08 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 |
| 18 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting |
| 21 Nov 2025 |
8-K: Termination of a Material Definitive Agreement
On November 18, 2025, in connection with its decision not to pursue further development of CLN-617, Cullinan Amber Corp. (the "Company"), a subsidiary of Cullinan Therapeutics, Inc. notified Massachusetts Institute of Technology ("MIT") ... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be presented in oral presentation at A... |
| 03 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting |
| 04 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Important Notice and Disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this... |
Loading...